Panobinostat is under clinical development by Pharmaand and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase II drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Panobinostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Panobinostat overview

Panobinostat (Farydak) is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. It is formulated as hard gelatin capsules for the oral route of administration. Panobinostat is indicated in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent.

Panobinostat (LBH589) is under development for the treatment of sickle cell disease, HIV-1 infections. The drug candidate was also under development for the treatment of pediatric patients with diffuse intrinsic pontine glioma (DIPG), graft versus host disease (GVHD), Huntington's disease, hematological tumors such as thyroid cancer, multiple myeloma, acute myelocytic leukemia, myelodysplastic syndrome, diffuse large B-cell lymphoma, thrombocythaemia myelofibrosis, myelofibrosis, refractory cutaneous T-cell lymphoma, post-polycythemia vera myelofibrosis (PPV-MF), acute lymphocytic leukemia, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, recurrent high grade glioma, chronic lymphocytic leukemia (CLL), esophageal cancer, gastric cancer, colorectal cancer, head and neck cancer, Hodgkin lymphoma, small-cell lung cancer, adult T-cell lymphoma, mantle cell lymphoma, thyroid cancer, adult T-cell leukemia, chronic myelocytic leukemia, osteosarcoma, malignant rhabdoid tumor, atypical teratoid rhabdoid tumor (MRT/ATRT), and neuroblastoma, non-small cell lung cancer, hepatocellular carcinoma, metastatic melanoma, HER -2 positive metastatic breast cancer, neuroendocrine tumors, metastatic renal cell carcinoma, refractory chronic myelocytic leukemia and recurrent malignant gliomas.

Pharmaand overview

pharmaand (Pharma), formerly Zr Pharma, is a manufacturer and distributor of pharmaceutical products. The company acquires and markets the authorization and worldwide rights of different products in various therapeutic areas such as urology, cardiovascular diseases and diseases of the central nervous system, gastroenterology, pneumology, and haematology, for patients and doctors worldwide. Its product offerings include coated tablets, divisible tablets, injections, gastro-resistant tablets, syrups, and capsules. The company’s service offerings include product development, distribution services, and lifecycle management. It markets its products through its brands such as Anafranil, Androskat, Asacol, Dridase, Emselex, Euphyllin, Farydak, Levact, and Pegasys. Pharma is headquartered in Vienna, Austria.

For a complete picture of Panobinostat’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.